Fieldview Capital Management, LLC Crispr Therapeutics Ag Transaction History
Fieldview Capital Management, LLC
- $648 Billion
- Q4 2024
A detailed history of Fieldview Capital Management, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Fieldview Capital Management, LLC holds 6,857 shares of CRSP stock, worth $358,072. This represents 0.04% of its overall portfolio holdings.
Number of Shares
6,857Holding current value
$358,072% of portfolio
0.04%Shares
1 transactions
Others Institutions Holding CRSP
# of Institutions
483Shares Held
64.1MCall Options Held
1.64MPut Options Held
1.93M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.97MShares$469 Million3.09% of portfolio
-
Capital International Investors Los Angeles, CA8.74MShares$457 Million0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.81MShares$199 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$145 Million0.0% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.75MShares$143 Million0.07% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.07B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....